Bridgeway Capital Management’s Alpine Immune Sciences Inc ALPN Stock Holding History

Bridgeway Capital Management’s Portfolio ALPN Stock Details ALPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-70,611	Closed	-$508K	–	1477
2022 Q3	$508K	Sell	70,611 -25,000	-26%	-$206K	0.01%	891
2022 Q2	$814K	Sell	95,611 -50,000	-34%	-$431K	0.02%	773
2022 Q1	$1.31M	Hold	145,611	–	–	0.03%	717
2021 Q4	$2.02M	Sell	145,611 -8,000	-5%	-$99.1K	0.04%	612
2021 Q3	$1.64M	Hold	153,611	–	–	0.03%	696
2021 Q2	$1.38M	Buy	+153,611	New	+$1.67M	0.02%	747
2019 Q2	–	Sell	-35,750	Closed	-$245K	–	1408
2019 Q1	$245K	Hold	35,750	–	–	﹤0.01%	1195
2018 Q4	$132K	Sell	35,750 -3,000	-8%	-$14.8K	﹤0.01%	1270
2018 Q3	$245K	Hold	38,750	–	–	﹤0.01%	1286
2018 Q2	$293K	Hold	38,750	–	–	﹤0.01%	1252
2018 Q1	$310K	Hold	38,750	–	–	﹤0.01%	1196
2017 Q4	$434K	Buy	38,750 +20,000	+107%	+$218K	﹤0.01%	1139
2017 Q3	$218K	Buy	+18,750	New	+$175K	﹤0.01%	1267
2017 Q2	–	Sell	-18,750	Closed	-$219K	–	1481
2017 Q1	$219K	Hold	18,750	–	–	﹤0.01%	1257
2016 Q4	$168K	Hold	18,750	–	–	﹤0.01%	1334
2016 Q3	$610K	Hold	18,750	–	–	0.01%	996
2016 Q2	$345K	Hold	18,750	–	–	0.01%	1186
2016 Q1	$313K	Buy	+18,750	New	+$375K	0.01%	1202

Other funds holding ALPN

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Bridgeway Capital Management's ALPN Position: Q4 2022 in Review

Bridgeway Capital Management sold out of Alpine Immune Sciences Inc (ALPN) in Q4 2022, closing a stake of 70,611 shares — an estimated $508K sold.

Bridgeway Capital Management first reported a position in ALPN in Q1 2016 and held it in 18 quarters. The position peaked at $2.02M in Q4 2021. 62 funds tracked by Wall St. Rank hold ALPN as of Q4 2022.

Bridgeway Capital Management reported no remaining Alpine Immune Sciences Inc position as of Q4 2022 after selling out during the quarter.
Bridgeway Capital Management sold 70,611 Alpine Immune Sciences Inc shares in Q4 2022, an estimated $508K.
Bridgeway Capital Management first reported a position in Alpine Immune Sciences Inc in Q1 2016 and held it in 18 quarters.
Bridgeway Capital Management's Alpine Immune Sciences Inc position peaked at $2.02M in Q4 2021.
62 funds tracked by Wall St. Rank held Alpine Immune Sciences Inc as of Q4 2022.

Based on Bridgeway Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.